Hosted on MSN
Arrowhead outlines REDEMPLO expansion with $60,000 annual price and expects top-line SHASTA-3/4 data in Q3 2026
Dr. Christopher Anzalone, CEO, announced Arrowhead’s first FDA approval for REDEMPLO, marking a major milestone as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback